Key Differences Among ALK Inhibitors

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Elizabeth Castronovo, NP

Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

Now Viewing

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

ALK Inhibitor Comparison and CNS Penetration

Key Themes:

Overview of currently available ALK inhibitors in the metastatic setting
Comparative analysis of efficacy and durability of response
Differences in CNS penetration among ALK inhibitors

Notable Insights:

Dr Lovly provided a comprehensive overview of available ALK inhibitors and their comparative efficacy

Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!